# Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer

> **NCT07466303** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Xijing Hospital** · enrollment: 84 (estimated)

## Conditions studied

- Breast Cancer
- Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer

## Interventions

- **DRUG:** Serplulimab
- **DRUG:** SHR-A1811

## Key facts

- **NCT ID:** NCT07466303
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-25
- **Primary completion:** 2028-02-01
- **Final completion:** 2031-04-01
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07466303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07466303, "Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07466303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*